ChemotherapyFDA-approvedFirst-line
Nab-paclitaxel
How it works
Nab-paclitaxel is a formulation of paclitaxel that is attached to albumin, allowing it to be delivered directly to cancer cells and reducing side effects.
Cancer types
Pancreatic Cancer— All patients
Efficacy
In clinical trials, nab-paclitaxel improved overall survival in patients with pancreatic cancer, with a median overall survival of approximately 6.7 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Gemcitabine and Nab-Paclitaxel for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Gemcitabine and Nab-paclitaxel with TheraBionic P1 for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing AMP945 with Nab-paclitaxel and Gemcitabine for Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| New Chemotherapy Combination Shows Promise for Pancreatic Cancer | Pancreatic Cancer | phase-2 | The 6-month progression-free survival rate was 71.0% (95% CI: 57.6%-80.9%). | Source → |
| Pancreatic Cancer Trial Investigates New Combination Therapy | Pancreatic Cancer | phase-2 | — | Source → |
| Pancreatic Cancer Treatment Trial: Surufatinib, Gemcitabine, and Nab-Paclitaxel | Pancreatic Cancer | phase-2 | — | Source → |
| Combination Therapy Trial for Metastatic Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Testing ONT01 with Gemcitabine and Nab-paclitaxel for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combination Therapy Shows Promise for Small-Cell Lung Cancer | Lung Cancer | phase-2 | The median progression-free survival was 6.0 months in the ANNAB group and 4.7 months in the NAP group (p = 0.0004). | Source → |
| Testing Combination Therapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a Combination Treatment for Unresectable Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combination Therapy for Resectable Pancreatic Cancer Before Surgery | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Fostamatinib with Chemotherapy in Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing a New Treatment for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| First-line Treatment Study for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-3 | — | Source → |
| Comparing Two Cancer Treatments for Ovarian Cancer | Ovarian Cancer | observational | The frequency of peripheral neuropathy in the nab-paclitaxel cohort (14%) was half that of the paclitaxel cohort (28%). | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer | Ovarian Cancer | phase-2 | A 1-month improvement in median progression-free survival and overall survival improvement was seen in the combination arm versus single-agent nab-paclitaxel. | Source → |
| Comparing Treatments for Early Recurring Pancreatic Cancer | Pancreatic Cancer | observational | The gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group. | Source → |
| Combining Radiation and Chemotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-1 | The median overall survival was 22.3 months. | Source → |
| Gemcitabine and Nab-paclitaxel Combination Therapy Linked to Lung Disease in Pancreatic Cancer Patients | Pancreatic Cancer | meta-analysis | — | Source → |
| Rare Side Effect of Cancer Treatment Affects Vision | Pancreatic Cancer | observational | — | Source → |
| Real-world Outcomes for Pancreatic Cancer Treatment | Pancreatic Cancer | review | In 9/17 clinical studies, median overall survival (mOS) ranged from 4.7 months to 11.4 months for FFX/mFFX, with the unweighted median of the estimates within this range being 9.2 months. | Source → |
| Combining Nadunolimab with Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer | Pancreatic Cancer | phase-2 | The median overall survival was 13.2 months, and the 1-year survival rate was 58%. | Source → |
| Comparing Chemotherapy Options for Advanced Pancreatic Cancer | Pancreatic Cancer | meta-analysis | — | Source → |
| Factors Affecting Chemotherapy-Induced Peripheral Neuropathy in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | — | Source → |
| Combining two treatments may slow pancreatic cancer growth | Pancreatic Cancer | animal-study | Sel-GemPac enhanced the survival of treated mice compared to controls (p < .05). | Source → |
| New Cancer Treatment Combination Shows Promise in Pancreatic Cancer | Pancreatic Cancer | phase-1/2 | Among the 21 patients treated at the maximum tolerated dose, 6 (29%) experienced partial response, and median progression-free survival and overall survival times were 11.0 months and 16.2 months, respectively. | Source → |
| Combining Gemcitabine and Nab-Paclitaxel in Ovarian Cancer Treatment | Ovarian Cancer | observational | The median progression-free survival was 9 months (95% CI, 5.7-20.7). | Source → |
| New Chemotherapy Combination Shows Promise for Triple-Negative Breast Cancer | Breast Cancer | phase-2 | After NAC, total pathological complete response was observed in 43.1% of patients. | Source → |
| Comparing Treatments for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The adjusted difference in median overall survival was 3.2 months (95% CI, 1.1-7.4) for FOLFIRINOX compared to gemcitabine plus nab-paclitaxel. | Source → |
| Atezolizumab and Nab-Paclitaxel Combination in Advanced Breast Cancer | Breast Cancer | observational | Median progression-free survival was 3.0 months (95% CI [2.5; 3.5]) and median overall survival was 8.94 months (95% CI [4.35; 13.53]). | Source → |
| New Insights into Pancreatic Cancer Treatment | Pancreatic Cancer | review | — | Source → |
| Gemcitabine plus nab-paclitaxel for elderly pancreatic cancer patients | Pancreatic Cancer | observational | The median overall survival was 10.8 months in the gemcitabine plus nab-paclitaxel group. | Source → |
| Gemcitabine and Nab-Paclitaxel Not Cost-Effective for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | Mean survival was lower for patients in the Gem-Nab than the FOLFIRINOX group (0.98 vs 1.26 life-years; incremental effectiveness = -0.28 life-years [95% confidence interval = -0.47 to -0.13]). | Source → |
| Testing Chemotherapy and Radiation for Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Gemcitabine and nab-paclitaxel in older patients with pancreatic cancer | Pancreatic Cancer | observational | Median progression-free survival was 5.5 months, and overall survival was 12.0 months in the older group. | Source → |
| Comparing Treatments for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The median disease control rates were 82.6% for gemcitabine with nab-paclitaxel and 67.9% for modified FOLFIRINOX. | Source → |
| Combination Chemotherapy May Help Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | The rate of progressive disease after three cycles of chemotherapy was reduced from 45.6% with gemcitabine to 25.4% with the combination of Nab-paclitaxel and gemcitabine. | Source → |
| Atezolizumab Plus Nab-Paclitaxel Therapy for Advanced Breast Cancer: Cost-Effectiveness in Japan | Breast Cancer | phase-3 | The QALYs for AnP treatment were longer than for nP treatment (1.12 vs 0.82 QALYs), but the total cost of AnP treatment was more expensive than that of nP treatment (¥11,070,143 vs ¥2,056,164). | Source → |
| Comparing Chemotherapy Options for Pancreatic Cancer | Pancreatic Cancer | review | FOLFIRINOX had significantly better overall survival (OS) and relapse-free survival (RFS)/disease-free survival (DFS)/progression-free survival (PFS) compared to gem-cap and gem-nab/P. | Source → |
| Cancer Treatment for Breast Cancer Patients Has Challenges | Breast Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.